Clinical trial NCT05293964: Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
Official title: A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Efficacy of SIM0270 Alone or in Combination in Subjects with ER-positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Breast Cancer
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Nanjing Zaiming Pharmaceutical Co., Ltd.
First posted: 2022-03-24
Enrollment: 214
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study is a multi-center, open-label, Phase 1 clinical study to evaluate the safety, pharmacokinetic (PK) and anti-tumor efficacy of SIM0270 and SIM0270 in combination with palbociclib or everolimus in subjects with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.

Detailed description: The study is comprised of two parts: Phase Ia and Phase Ib. Phase Ia includes dose-escalating stage and dose expansion stageof SIM0270 monotherapy to determine the MTD/ RP2D and the preliminary safety and efficacy of SIM0270; Phase Ib includes 2 arms, armA: dose escalation and dose expansion of SIM0270 in combination with palbociclib; armB: dose escalation and dose expansion of SIM0270 in combination with palbociclib everolimus; phase Ib is designed to determine the MTD/RP2D and the preliminary safety and efficacy of SIM0270 in combination with palbociclib or everolimus.

Eligibility criteria: key Inclusion Criteria:

1. voluntary participation in clinical trials and signature of informed consent.
2. age ≥ 18 years, male or female.
3. Histologically or cytologically confirmed metastatic/locally advanced ER-positive, HER-2 negative breast cancer subjects.
4. previous treatment meets the criteria of the protocol defined.
5. ECOG score of 0 or 1 .
6. at least one measurable lesion that meets RECISTv1.1 criteria. Osteolytic lesions can be included in the Ia dose-escalating .
7. expected survival ≥ 12 weeks.
8. Adequate organ and bone marrow function.
9. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose.
10. Postmenopausal women; Premenopausal or perimenopausal female subjects met protocol requirements.

key Exclusion Criteria:

1. Documented medical history or ongoing gastrointestinal disease or other malabsorption that may affect the absorption of oral study drug.
2. Participated in other clinical trials of investigational drugs or investigational devices within 28 days before the first medication; or received chemotherapy, targeted therapy, immunotherapy and clinical trial medication and other anti-tumor treatment within 4 days or 5 half-lives of the first medication (whichever is shorter), or received radiotherapy, endocrine drugs or Chinese patent medicines with anti-tumor indications 2 weeks before the first medication;
3. The toxicity of previous anti-tumor treatment has not recovered to grade 0 or 1 (alopecia, chemotherapy-induced peripheral neurotoxicity ≤ grade 2 can be included).
4. Major surgical surgery (except biopsy) or incomplete healing of the surgical incision 4 times before the first study drug treatment;
5. Known other malignant tumors within 2 years before enrollment (except treated basal cell carcinoma, scaly cell carcinoma and/or radical carcinoma in situ);
6. Leptomeningeal metastasis confirmed by MRI or known cytology of CSF, or cranial Increased internal pressure or brain metastases with unstable central nervous symptoms (within 2 weeks prior to initial medication Treatment with any craniotropic, glucocorticokinin, or anticonvulsant);
7. Previous history of interstitial lung disease, drug-induced interstitial lung disease, symptomatic interstitial lung disease or any evidence of active pneumonia on chest CT scan 4 before the first study drug treatment;
8. known to interfere with the test requirements of mental illness or drug abuse disease.
9. History of human immunodeficiency virus HIV infection, or active bacterial or fungal infection requiring systemic treatment .
10. presence of active syphilis infection.
11. Subjects with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with abnormal liver function.
12. History of clinically significant cardiovascular disease.
13. History of serious allergic reactions to the study drugs or excipients used in the protocol.
14. Women who are pregnant or lactating.
15. Prior use of SERD oral medications.
16. Subjects who use drugs or herbal supplements known to be moderate/strong inhibitors of CYP3A 2 Weeks before the first dose.Or Subjects who use drugs or herbal supplements known to be moderate/strong inducers of CYP3A 4 weeks before the first dose.
17. Other conditions that the investigator considers unsuitable for this study.

Primary outcomes:
measure: Maximum Tolerated Dose
timeFrame: At the end of Cycle 1 (each cycle is 28 days)
measure: recommended phase 2 Dose
timeFrame: At the end of Cycle 1 (each cycle is 28 days)
measure: Dose-Limiting Toxicities
timeFrame: At the end of Cycle 1 (each cycle is 28 days)
Secondary outcomes:
measure: Adverse event
timeFrame: From Baseline until 30 days after the last dose of study treatment
measure: Peak Plasma Concentration (Cmax) of SIM0270 as monotherapy or combination with palbociclib or everolimus
timeFrame: At the end of Cycle 4 (each cycle is 28 days)
measure: Time of Peak Plasma Concentration (Tmax) of SIM0270 as monotherapy or combination with palbociclib or everolimus
timeFrame: At the end of Cycle 4 (each cycle is 28 days)
measure: Area under the plasma concentration versus time curve (AUC) of SIM0270 as monotherapy or combination with palbociclib or everolimus
timeFrame: At the end of Cycle 4 (each cycle is 28 days)
measure: clinical benefit rate
timeFrame: through study completion, an average of 1 year
measure: disease control rate
timeFrame: through study completion, an average of 1 year
measure: duration of response
timeFrame: through study completion, an average of 1 year
measure: progression free survival
timeFrame: From date of C1D1 until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
measure: time to progression
timeFrame: From date of C1D1 until the date of first documented progression, assessed up to100 months
measure: time to response
timeFrame: through study completion, an average of 1 year
measure: overall survival
timeFrame: From date of C1D1 until the date of death from any cause, assessed up to 100 months
measure: overall response rate
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
affiliation: chief physician
name: Jiong Wu, phD
role: PRINCIPAL_INVESTIGATOR
References: